FDA Review Finds Insufficient Data on Pfizer's COVID-19 Vaccine Safety for Vulnerable Groups

Strategic Insights -

The recent FDA review of Pfizer's coronavirus vaccine found insufficient data to conclude whether the vaccine is safe for children under 16, pregnant women, and immunocompromised individuals. The review also questions the safety of vaccinating individuals who previously got COVID-19, particularly if they have lingering symptoms. Experts worry that vaccinating these groups without more safety data could lead to unforeseen complications.

Key Takeaways:

  • Children under 16 only represent around 7% of confirmed coronavirus infections in the US, and their low risk of severe disease makes them a lower priority for vaccinations.
  • Pregnant women were excluded from Pfizer's trials, and researchers don't know how the vaccine affects pregnant women yet; it's essential to get this data as soon as possible, as pregnant women are at high risk for COVID-19 complications.
  • HIV-positive individuals and others with weakened immune systems must wait for more data on the vaccine's safety, as the trials only included a small number of HIV-positive individuals, and serious adverse events were only reported in 0.6% of vaccine recipients.
  • Pfizer's vaccine relies on a snippet of the virus' genome to trigger an immune response, but immunocompromised people may require extra doses or want to avoid getting vaccinated while taking immunosuppressants.
  • People who previously got COVID-19 are in a grey area, as studies suggest these patients may have immunity to the virus that lasts several months to several years, but the research is far from conclusive.
  • Long-haulers may face intensification of an already aggressive immune response with a vaccine, making it essential to prioritize more safety data before vaccinating these patients.

Statistics:

  • 7% of confirmed coronavirus infections in the US are among children (CDC).
  • 0.6% of vaccine recipients experienced serious adverse events (FDA Review).
  • 3% of Pfizer's late-stage clinical trial participants had been infected with COVID-19 before the trial (Business Insider).
  • Pregnant women with COVID-19 are more likely to be admitted to the ICU, put on ventilators, and die than patients who aren't pregnant (CDC).
  • 51% of women who gave birth in 2019 were white, but only 24% of symptomatic pregnant women with COVID-19 were white (CDC).

Sources:

  • FDA (Food and Drug Administration) review of Pfizer's COVID-19 vaccine (https://www.fda.gov/media/144245/download)
  • Business Insider article on Pfizer's COVID-19 vaccine and its safety for vulnerable groups (https://www.businessinsider.com/pfizer-coronavirus-vaccine-kids-pregnant-women-immunocompromised-2020-12)
  • Centers for Disease Control and Prevention (CDC) report on COVID-19 in pregnant women (https://www.cdc.gov/mmwr/volumes/69/wr/mm6944e3.htm#:~:text=Whereas%20increased%20risk%20for%20severe,women%20of%20the%20same%20age.)
  • World Health Organization (WHO) report on the safety of flu vaccines during pregnancy (https://www.who.int/vaccine_safety/publications/safety_pregnancy_nov2014.pdf)